Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUE-102 in WT1-positive recurrent/metastatic cancers
NCT05360680Phase 1Completed
- Sponsor
- Cue Biopharma
- Start
- Jun 2022
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Immunotoxins
- Countries
- 1
01
Overview
Phase 1, open-label trial of CUE-102 in colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PC) and 1 more (5 arms), sponsored by Cue Biopharma. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 3 more. Started Jun 2022; status: completed.
02
Drugs
CUE-102
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)pancreatic cancer (PC)ovarian cancer
Beyond the preview
Go deeper on NCT05360680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360680.